現在位置 : 藥物 > 消化性潰瘍藥 - Rabeprazole (Pariet, 百抑潰)

抑制胃酸藥 (消化性潰瘍藥)
Pariet = Rabeprazole  (質子泵抑制劑) 
      抑制胃酸的藥物可分為 (一) H2受體阻斷劑 (二) 質子泵抑制劑。此類藥物可舒緩疼痛、胃灼熱、消化不良等徵狀。藥物可掩蓋胃癌病變所引起的徵狀，所以服藥前應徵詢醫生意見，排除出現惡性腫瘤的可能性才可使用，以免延誤診治。 質子泵抑制劑有抑制H+/K+-ATPase 酶的作用，直接阻止酸的產生，從而抑制胃酸的分泌，作用強而持久，如esomeprazole、omeprazole、lansoprazole、rabeprazole、 pantoprazole等。此類藥物可用於預防及治療消化性潰瘍，有促進胃及十二指腸潰瘍癒合作用。
      治療消化性潰瘍一般為期六至八星期。
      質子泵抑制劑與另外兩種抗生素聯合使用一星期，可殺滅導致消化性潰瘍的幽門螺旋桿菌。
      口服藥物一般每日一次，用於殺滅幽門螺旋桿菌的治療需每日服藥兩次。
      服藥時間無須配合用餐，但有建議餐前服用pantoprazole。藥物經肝酵素代謝，肝病患者應小心使用。
      常見副作用有頭痛、腹痛、噁心、嘔吐、腹瀉、便秘、脹氣等。
      孕婦及哺乳期婦女服藥前必須徵詢醫生意見。

Rabeprazole Pariet tab 20mg

Rabeprazole (Pariet) (百抑潰)
      Rabeprazole is an antiulcer drug in the class of proton pump inhibitors. It was developed by Eisai Co. and is marketed by Janssen-Cilag as the sodium salt under the brand names AcipHex (referring to pH) in the US, Pariet in Europe, Brazil, Canada, Japan, Russia and Australia. Rabonik in India, and Zechin in Pakistan.In Bangladesh Rabeprazole is sold under the brand name of Acifix by Beximco Pharma.
Proton-Pump Inhibitors (質子泵抑制劑)
      Proton-pump inhibitors (PPIs) are a group of drugs whose main action is a pronounced and long-lasting reduction of gastric acid production. They are the most potent inhibitors of acid secretion available. The group followed and has largely superseded another group of pharmaceuticals with similar effects, but a different mode of action, called H2-receptor antagonists. These drugs are among the most widely sold drugs in the world, and are generally considered effective. The vast majority of these drugs are benzimidazole derivatives, but promising new research indicates the imidazopyridine derivatives may be a more effective means of treatment. High dose or long-term use of PPIs carries a possible increased risk of bone fractures.

Rabeprazole Pariet tab 20mg (Taipei VGH)

Indications and usage
       Short-term treatment in healing and symptomatic relief of duodenal ulcers and erosive or ulcerative gastroesophageal reflux disease (GERD); maintaining healing and reducing relapse rates of heartburn symptoms in patients with GERD; treatment of daytime and nighttime heartburn and other symptoms associated with GERD; long-term treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome and in combination with amoxicillin and clarithromycin to eradicate Helicobacter pylori.
● Gastric ulcer (GU)
● Peptic ulcer disease (PUD)
● Maintenance of healing of erosive or ulcerative GERD
● Healing of erosive and ulcerative GERD
● Healing of duodenal ulcers.
● Treatment of symptomatic GERD
● Treatment of pathological hypersecretory conditions (Zollinger-Ellison syndrome)
● Helicobacter pylori eradication to reduce risk of duodenal ulcer recurrence
Contraindications
● hypersensitivity to rabeprazole, substituted benzimidazoles or any of components of its pharmaceutical forms.
● lactation: Thomson Lactation Ratings: Infant risk cannot be ruled out.
Restriction of usage
● acute hepatic failure
● pediatric use in patients under 18 years of age (there are insufficient data about safety and efficiency of rabeprazole in this group of patients)
Side effects
      Rabeprazole adverse reactions/side effects include:
In clinical trials the most common side effect assessed as possibly or probably related to AcipHex was headache in 2.4% of patients vs 1.6% taking placebo.
● abdominal pains
● anxiety
● arthralgia
● asthenia
● constipation
● diarrhea
● dry mouth
● erythema
● granulocytopenia
● headache
● increased or decreased appetite
● insomnia
● leukocytopenia
● meteorism
● muscle or bone pain
● myalgia
● nausea
● skin eruption
● thrombocytopenia
● vertigo
● vomiting
       Antacid preparations such as rabeprazole by suppressing acid mediated break down of proteins, leads to an elevated risk of developing food or drug allergies. This happens due to undigested proteins then passing into the gastrointestinal tract where sensitisation occurs. It is unclear whether this risk occurs with only long-term use or with short-term use as well.
Drug interactions
      Rabeprazole decreases the concentration of ketoconazole in the plasma (in 33%), increases the concentration of digoxin (in 22%), and does not interact with liquid antacids. Rabeprazole is compatible with any medicine metabolized by the CYP450 (theophylline, warfarin, diazepam, phenytoin).
Overdosage
      Studies in mice and rats indicated the symptoms of acute toxicity due to overdose included: hypoactivity, labored respiration, convulsion, diarrhea, tremor, and coma. A study in dogs indicated that a dose of 2000mg/kg was not lethal.
Formulations and brand names
      Rabeprazole as "Rabonik" (Eris Life Sciences), "CYRA" (Systopic Labs Pvt Ltd), "Elpizole" (Orchid Chemicals & Pharmaceuticals), Elpizole-20 (Orchid Chemicals & Pharmaceuticals), Rablet (Lupin), Acigard (3D), AcipHex, Rabeloc, Pariet, Rabider (Duta Formulations) Rabsiv 20 (Saharsh Biologicals) is supplied in:
● Tablet, enteric-coated; 10 mg
● Tablet, enteric-coated; 20 mg

Click here to edit.